NXY-059


Also found in: Wikipedia.

NXY-059

A free radical-trapping agent that has been found to be neuroprotective in stoke in animals. It has been tested in ischaemic stroke in humans and was found to reduce disability at 90 days but did not improve putcome in other respects.
References in periodicals archive ?
Lyden et al., "NXY-059 for the treatment of acute ischemic stroke," The New England Journal of Medicine, vol.
In 2004, a clinical trial demonstrated the effectiveness of NXY-059 compound (another PBN derivative) in patients with ischemic stroke, even when concentrations higher than 260 [micro]M of the compound were administrated intravenously [26].
The recently published Cerebral Hemorrhagic and NXY-059 Treatment Trial found no relationship between prior antiplatelet use and the volume of ICH on baseline CT, ICH growth, or clinical outcome at 90 days.
Lees et al., "Safety and tolerability of NXY-059 for acute intracerebral hemorrhage: the CHANT trial," Stroke, vol.
Green, "Effects of NXY-059 in experimental stroke: an individual animal meta-analysis," British Journal of Pharmacology, vol.
The trial found no significant benefit to stroke patients from an antioxidant called NXY-059, which was intended to inhibit damage by free radicals.
The news comes at a difficult time for AstraZeneca, which was relying on established medicines such as Nexium to drive sales following the failure of clinical trials for new drugs, such as stroke drug NXY-059.
The UK's second-largest drug makers ended development of the NXY-059 treatment after patients showed no improvement during clinical trials.
The UK's second-largest drugmaker ended development of the NXY-059 treatment after patients showed no improvement during the tests.
A trial involving more than 1,700 patients in 154 hospitals around the world found that the treatment, currently known as NXY-059, has produced "promising" results.
Green, "Investigating the free radical trapping ability of NXY-059, S-PBN and PBN," Free Radical Research, vol.